Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Enterprise Value (2019 - 2026)

InMed Pharmaceuticals has reported Enterprise Value over the past 5 years, most recently at -$7.0 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 451.23% year-over-year to -$7.0 million; the TTM value through Dec 2025 reached -$7.0 million, down 451.23%, while the annual FY2025 figure was -$11.1 million, 68.1% down from the prior year.
  • Enterprise Value for Q4 2025 was -$7.0 million at InMed Pharmaceuticals, up from -$9.4 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$1.3 million in Q4 2024 and troughed at -$15.4 million in Q3 2021.
  • A 5-year average of -$7.6 million and a median of -$7.0 million in 2025 define the central range for Enterprise Value.
  • Biggest five-year swings in Enterprise Value: soared 88.23% in 2023 and later plummeted 451.23% in 2025.
  • Year by year, Enterprise Value stood at -$11.3 million in 2021, then fell by 1.5% to -$11.5 million in 2022, then soared by 88.23% to -$1.4 million in 2023, then grew by 5.53% to -$1.3 million in 2024, then plummeted by 451.23% to -$7.0 million in 2025.
  • Business Quant data shows Enterprise Value for INM at -$7.0 million in Q4 2025, -$9.4 million in Q3 2025, and -$11.1 million in Q2 2025.